[Use of cerebrolysin in the treatment of prolonged extrapyramidal complications of neuroleptic therapy].

Kontsevoĭ VA, Medvedev AV, Andrusenko MP, Zvenigorodskaia IuV, Sheshenin VS

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 1997

PMID11517474PepBankPUB-11517474

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with tardive dyskinesia or parkinsonism, extrapyramidal symptom severity decreased significantly after Cerebrolysin therapy.
In plain wordsIn patients with tardive dyskinesia or parkinsonism, movement symptom severity decreased after Cerebrolysin therapy.
Peptide
Cerebrolysin
Outcome
DecreaseExtrapyramidal symptom severity
Study
n = 30
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
5-10 ml every other day · intravenous · 28 daysAs given in this study (human).
Source sentences
Summary
Significant decrease of the severity of extrapyramidal symptoms (according to the Scales used) was observed by the end of the course of therapy.
3 context sentences(design, population, supporting numbers)
Summary · context
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism.
Summary · context
30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale.
Summary · context
Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days.
Report a problemFND-1151747401
02HumanNon-randomized trialEfficacy outcome
In patients with extrapyramidal disorders, 46.6% responded to Cerebrolysin therapy.
In plain wordsIn patients with extrapyramidal disorders, 46.6% responded to Cerebrolysin therapy.
Peptide
Cerebrolysin
Outcome
Not applicableResponder proportion
Study
n = 30
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
5-10 ml every other day · intravenous · 28 daysAs given in this study (human).
Measurements
Responders
46.6%
all patients
Source sentences
Summary
The number of the responders was 46.6%, of the partial responders--26.6%.
3 context sentences(design, population, supporting numbers)
Summary · context
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism.
Summary · context
30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale.
Summary · context
Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days.
Report a problemFND-1151747402
03HumanNon-randomized trialEfficacy outcome
In patients with extrapyramidal disorders, 26.6% partially responded to Cerebrolysin therapy.
In plain wordsIn patients with extrapyramidal disorders, 26.6% partially responded to Cerebrolysin therapy.
Peptide
Cerebrolysin
Outcome
Not applicablePartial responder proportion
Study
n = 30
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
5-10 ml every other day · intravenous · 28 daysAs given in this study (human).
Measurements
Partial responders
26.6%
all patients
Source sentences
Summary
The number of the responders was 46.6%, of the partial responders--26.6%.
3 context sentences(design, population, supporting numbers)
Summary · context
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism.
Summary · context
30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale.
Summary · context
Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days.
Report a problemFND-1151747403
04HumanNon-randomized trialEfficacy outcome
In patients with drug-induced parkinsonism, the Cerebrolysin responder proportion was 54.5%.
In plain wordsIn patients with drug-induced parkinsonism, 54.5% responded to Cerebrolysin therapy.
Peptide
Cerebrolysin
Outcome
Not applicableParkinsonism responder proportion
Study
n: not reported in source
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
5-10 ml every other day · intravenous · 28 daysAs given in this study (human).
Measurements
Responders
54.5%
parkinsonism
Source sentences
Summary
Efficiency of cerebrolysin was the same both in the groups of patients with drug-induced parkinsonism (number of the responders--54.5%) and in patients with tardive dyskinesia (the responders' number--60%).
3 context sentences(design, population, supporting numbers)
Summary · context
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism.
Summary · context
30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale.
Summary · context
Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days.
Report a problemFND-1151747404
05HumanNon-randomized trialEfficacy outcome
In patients with tardive dyskinesia, the Cerebrolysin responder proportion was 60%.
In plain wordsIn patients with tardive dyskinesia, 60% responded to Cerebrolysin therapy.
Peptide
Cerebrolysin
Outcome
Not applicableTardive dyskinesia responder proportion
Study
n: not reported in source
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
5-10 ml every other day · intravenous · 28 daysAs given in this study (human).
Measurements
Responders
60%
tardive dyskinesia
Source sentences
Summary
Efficiency of cerebrolysin was the same both in the groups of patients with drug-induced parkinsonism (number of the responders--54.5%) and in patients with tardive dyskinesia (the responders' number--60%).
3 context sentences(design, population, supporting numbers)
Summary · context
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism.
Summary · context
30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale.
Summary · context
Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days.
Report a problemFND-1151747405
06HumanNon-randomized trialEfficacy outcome
Cerebrolysin efficacy was similar in patients with drug-induced parkinsonism and patients with tardive dyskinesia.
In plain wordsCerebrolysin efficacy was similar in patients with drug-induced parkinsonism and patients with tardive dyskinesia.
Peptide
Cerebrolysin
Outcome
No significant changeEfficacy by disorder
Study
n: not reported in source
Comparator
Tardive dyskinesia
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
5-10 ml every other day · intravenous · 28 daysAs given in this study (human).
Measurements
Responders
54.5%
Drug-induced parkinsonism group in the comparison with tardive dyskinesia
Responders
60%
Tardive dyskinesia group in the comparison with drug-induced parkinsonism
Source sentences
Summary
Efficiency of cerebrolysin was the same both in the groups of patients with drug-induced parkinsonism (number of the responders--54.5%) and in patients with tardive dyskinesia (the responders' number--60%).
3 context sentences(design, population, supporting numbers)
Summary · context
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism.
Summary · context
30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale.
Summary · context
Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days.
Report a problemFND-1151747406
07HumanNon-randomized trialEfficacy outcome
Cerebrolysin efficacy was lower in patients with combined parkinsonism and tardive dyskinesia symptoms.
In plain wordsCerebrolysin efficacy was lower in patients with combined parkinsonism and tardive dyskinesia symptoms.
Peptide
Cerebrolysin
Outcome
DecreaseEfficacy with combined symptoms
Study
n: not reported in source
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
5-10 ml every other day · intravenous · 28 daysAs given in this study (human).
Source sentences
Summary
The efficiency of cerebrolysin was lower in patients with combination of symptoms of parkinsonism and tardive dyskinesia as well as in ones with pronounced negative schizophrenic disorders in clinical picture.
3 context sentences(design, population, supporting numbers)
Summary · context
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism.
Summary · context
30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale.
Summary · context
Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days.
Report a problemFND-1151747407
08HumanNon-randomized trialEfficacy outcome
Cerebrolysin efficacy was lower in patients with pronounced negative schizophrenic disorders.
In plain wordsCerebrolysin efficacy was lower in patients with pronounced negative schizophrenic disorders.
Peptide
Cerebrolysin
Outcome
DecreaseEfficacy with negative schizophrenic disorders
Study
n: not reported in source
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
5-10 ml every other day · intravenous · 28 daysAs given in this study (human).
Source sentences
Summary
The efficiency of cerebrolysin was lower in patients with combination of symptoms of parkinsonism and tardive dyskinesia as well as in ones with pronounced negative schizophrenic disorders in clinical picture.
3 context sentences(design, population, supporting numbers)
Summary · context
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism.
Summary · context
30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale.
Summary · context
Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days.
Report a problemFND-1151747408
09HumanNon-randomized trialEfficacy outcome
Cerebrolysin efficacy was similar in patients of middle and old age.
In plain wordsCerebrolysin efficacy was similar in patients of middle and old age.
Peptide
Cerebrolysin
Outcome
No significant changeEfficacy by age
Study
n: not reported in source
Comparator
Old age
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
5-10 ml every other day · intravenous · 28 daysAs given in this study (human).
Source sentences
Summary
Efficacy of cerebrolysin was also the same in patients of both middle and old age.
3 context sentences(design, population, supporting numbers)
Summary · context
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism.
Summary · context
30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale.
Summary · context
Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days.
Report a problemFND-1151747409
10HumanNon-randomized trialEfficacy outcome
Cerebrolysin efficacy was similarly high across durations of extrapyramidal disorders.
In plain wordsCerebrolysin efficacy was similarly high across durations of extrapyramidal disorders.
Peptide
Cerebrolysin
Outcome
No significant changeEfficacy by disorder duration
Study
n: not reported in source
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
5-10 ml every other day · intravenous · 28 daysAs given in this study (human).
Source sentences
Summary
Its efficiency was equally high independently on the duration of extrapyramidal disorders' existence.
3 context sentences(design, population, supporting numbers)
Summary · context
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism.
Summary · context
30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale.
Summary · context
Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days.
Report a problemFND-1151747410

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.